Title : [Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI® Tablets 1 mg, 2 mg)].

Pub. Date : 2019

PMID : 31735758






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Brexpiprazole (Rexulti ) is the second antipsychotic agent in the world with dopamine D2 receptor partial agonist which was developed by Otsuka Pharmaceutical Co. Ltd. brexpiprazole dopamine receptor D2 Homo sapiens